Anti-CS1 CAR mRNA-LNP

CS1 (CD2 subset-1), also known as CD319 (SLAMF7), is a human natural killer (NK) cell receptor encoded by the SLAMF7 gene. This surface antigen is a robust marker of normal and malignant plasma cells in multiple myeloma. Human NK cells express two splice variants of CS1: CS1-S lacks an intracellular domain for activation, while CS1-L contains an intracellular domain and is therefore capable of activating NK cytotoxicity. CS1 is a homophilic receptor, and CS1-CS1 interaction leads to the activation of natural cytotoxicity of NK cells. Both isoforms of CS1 are membrane bound and expressed in NK cells. However, only the CS1-L isoform is expressed in B cells and regulates B cell proliferation and autocrine. This product is designed as a tool for the delivery and expression of anti-CS1 CAR mRNA for research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of anti-CS1 CAR mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. The anti-CS1 CAR in this product is approximately 56 kD and consists of anti-CS1 scFv (single-chain variable fragment) linked to a second-generation CAR (chimeric antigen receptor) containing the CD8 hinge and transmembrane domain and 4-1BB and CD3ζ signaling domains. The full-length amino acid sequence of this anti-CS1 CAR mRNA-LNP product is available upon request.